Rafferty Asset Management LLC Sells 6,156 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Rafferty Asset Management LLC decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 46,472 shares of the biopharmaceutical company’s stock after selling 6,156 shares during the quarter. Rafferty Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $26,130,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Dodge & Cox grew its holdings in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock valued at $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $628,151,000. Acadian Asset Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 234.7% during the 2nd quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock valued at $244,480,000 after buying an additional 326,583 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after acquiring an additional 305,089 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 26.5% during the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock valued at $564,808,000 after acquiring an additional 225,078 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 in the last three months. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of analyst reports. Canaccord Genuity Group increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a report on Monday, February 9th. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. HSBC upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Finally, Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Trading Up 1.4%

REGN stock opened at $781.67 on Friday. The firm’s 50-day moving average is $771.59 and its 200 day moving average is $681.65. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a market capitalization of $82.64 billion, a PE ratio of 18.81, a P/E/G ratio of 2.10 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $12.07 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: U.S. FDA approval (announced Feb. 24) expanding Dupixent’s indication to include allergic fungal rhinosinusitis — adds a new labeled population and supports future revenue growth. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: European Medicines Agency recommended Dupixent for approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved, this would be the first targeted EU therapy for that pediatric group, extending Dupixent’s addressable market. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
• Positive Sentiment: Analyst sentiment improved with Wall Street Zen moving REGN to a Buy rating — upgrades can spur additional investor interest and short-term flows. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Wall Street Zen
• Positive Sentiment: Media/analyst pieces and hedge-fund screens continue to highlight Regeneron as a top gene-therapy/big-pharma pick, reinforcing investor narratives around its pipeline and R&D capabilities. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: Dupixent sales momentum remains a core bull case — recent analysis notes ~22.8% YoY growth for Dupixent in Q4 and continued contribution to Regeneron’s top-line strength. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Neutral Sentiment: Coverage notes REGN has lagged the Nasdaq over the past year — a reminder of relative performance risk even amid positive fundamental catalysts. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.